Referring Clinician

Please email all referrals to CentralReferrals@adhb.govt.nz (including Att: ACTC in email subject)

NOTE: referrals only accepted from oncologists/haematologists.

Email us for any other queries: infoACTC@adhb.govt.nz

entries per page

Search:

Tumour Stream	Trial Name	Study Description	Key Investigational Agent	Key Inclusion Criteria	Recruitment Status
All Cancers	Beigene SMAC mimetic BGB-24714-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Smac Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced Solid Tumors	BGB-24714 (SMAC mimetic) +/- paclitaxel	• Measurable disease • ECOG PS 0-1 • Adequate organ function	Open
All Cancers	BGB-15025 and Tislelizumab in advanced solid tumours	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination with Anti-PD- 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors	BGB-15025 (oral HPK1 inhibitor) +/- tislelizumab	• Measurable disease • Must have biopsiable disease or archival tissue • ECOG PS 0-1 • Adequate organ function • No history of autoimmune disorders (please discuss with investigators)	Open
All Cancers	BGB-A317-26808-101 (HPK2)	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Ad-vanced Solid Tumors	BGB-26808 (HPK1 Inhibitor) +/- Tislelizumab		Open
All Cancers	BGB-53038-101 Pan-KRAS	A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmaco-dynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification	BGB-53038 (Pan-KRAS Inhibitor)		Open
All Cancers	MK6482-016	An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors	Pembrolizumab + Lenvatinib + Belzutifan		Open
All Cancers	TAPISTRY BO41932	Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial	• ALK – Alectinib • NTRK 1/2/3 - entrectinib • ROS – entrectinib • PIK3CA – inavolisib • RET -praseltinib (AKT, MDM2, HER2, BRAF & TMB high arms closed)	• At least 2L treatment or no acceptable treatment • Measurable disease • Must have archival tissue or biopsiable disease for NGS testing (FNA not allowed) • ECOG PS 0-1 • Adequate organ function • NSCLC not allowed for ALK/ROS arms	Open
All Cancers	ZION	A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients with HER2-Positive Advanced Solid Tumors	ZN-A-1041 (single agent or in combination)		Open
Breast/GI	APEC	Does the Concomitant Administration of Proton Pump Inhibitors Affect Capecitabine Pharmacokinetics? – A Prospective, Single-Centre, Two-Arm, Randomised, Unblinded, Cross-Over Bioequivalence Study of Capecitabine With or Without Concomitant Pantoprazole.	Pantoprazole	• At least 2 cycles of single agent capecitabine • CAPOX not permitted.	Open
Gastrointestinal	CITRON	Reducing Oxaliplatin Neurotoxicity: A Phase 1B Randomized, Double-Blind, Placebo- Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer Patients	Cimetidine	• At least 2 cycles of oxaliplatin-based chemotherapy • Must not have pre-existing >G1 peripheral neuropathy	Open
Lymphoma	BGB-11417-101	A Phase 1/1b Open-Label Dose Escalation and Expansion Study of the Bcl-2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib (BGB-3111) in Patients With Mature B-Cell Malignancies			Open

Showing 1 to 10 of 14 entries